http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101636108-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dee814b1ba7fddffa2ecdea48bf074f4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1875
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-055
filingDate 2007-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0455ba3717facc63558cdc854865385
publicationDate 2014-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101636108-B
titleOfInvention Imaging of activated vascular endothelium using immunomagnetic MRI contrast agents
abstract lmmunomagnetic nanoparticles are used as a contrast agent for enhancing medical diagnostic imaging such as magnetic resonance imaging (MRI). The present invention is directed to methods of making targeted MRI contrast agents from immunomagnetic particles, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents provide enhanced relaxivity, improved signal-to-noise, targeting ability, and resistance to agglomeration. Methods of making such MRI contrast agents typically afford better control over particle size, and methods of using such MRI contrast agents typically can afford enhanced blood clearance rates and distribution. The ability to use the contrast agents im MRI provides a tool in the diagnosis and treatment of several disease states.
priorityDate 2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6365362-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419578423
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID10095
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3383
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554059
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID430950201
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6432052
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID10095
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534378
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID125175
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453759058
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID55466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2724705
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88282129
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450540594
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419562155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527388
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25464
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403975
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID518696
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281839
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID15894
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4781
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2162

Total number of triples: 41.